Congruence Therapeutics
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $96M
Investors
- 9
About Congruence Therapeutics
Based in Montreal, Canada, and founded in 2021, Congruence Therapeutics Inc. operates as a biotechnology company that develops and discovers small molecules for protein misfolding diseases. Congruence Therapeutics Inc. is an inventor of a pharmacological stabilizer for the treatment of rare diseases. Additionally, the company deploys an in silico platform that enables the design of an established class of small molecules, assisting researchers in the design of biomolecules for protein misfolding diseases.
Who invested in Congruence Therapeutics
9 investors across 3 rounds
See all investors in Congruence Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Congruence Therapeutics
Who invested in Congruence Therapeutics?
Congruence Therapeutics has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Congruence Therapeutics raised?
Congruence Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Congruence Therapeutics last raise money?
Congruence Therapeutics's most recent round on record is a Series B, in Sep 2025.
What does Congruence Therapeutics do?
Based in Montreal, Canada, and founded in 2021, Congruence Therapeutics Inc.
Where is Congruence Therapeutics headquartered?
Congruence Therapeutics is headquartered in Montreal, Canada.
Which VCs invest in companies like Congruence Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Congruence Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Congruence Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.